Edgewise Therapeutics, Inc. (EWTX) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Boulder, CO, United States. वर्तमान CEO हैं Kevin Koch.
EWTX के पास है IPO तिथि 2021-03-26, 117 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $3.62B.
Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapies for musculoskeletal diseases, particularly rare genetic muscle disorders. The company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy, and has completed Phase 1 clinical trials. Edgewise is building a pipeline of precision medicine candidates that target key muscle proteins and modulators to treat genetically defined muscle disorders. Founded in 2017 and headquartered in Boulder, Colorado, the company is advancing innovative therapeutic approaches for patients with serious muscle-wasting conditions.
